DurAVR™ has been implanted in 50 patients (44 with severe aortic stenosis and six valve-in-valve cases
to rectify prosthetic valve failure). Clinical results to date demonstrate this new class of biomimetic valve
outperforms the market leader, returning patients to a near normal haemodynamic (blood flow) state.
Ann: Capital Raise, page-5
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M | |||
| Open | High | Low | Value | Volume |
| $18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 247 | 2 |
View Market Depth
| Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |